Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
Raphael Schiffmann(Texas Christian University), Robert J. Desnick(Icahn School of Medicine at Mount Sinai), William R. Wilcox(Emory University), Maryam Banikazemi(University of Alabama at Birmingham), Seymour Packman(University of California, San Francisco), Jan Bultas(Charles University), David G. Warnock(University of Alabama at Birmingham), S. A. Sørensen(University of Copenhagen), Gabor E. Linthorst(Geneeskundige en Gezondheidsdienst)
Cited by 366
Related Papers
Isolation of a candidate gene for Menkes disease and evidence that it encodes a copper–transporting ATPase
|Nature Genetics|1993|1.4k
Elevated globotriaosylsphingosine is a hallmark of Fabry disease
|Proceedings of the National Academy of Sciences|2008|725
Agalsidase-Beta Therapy for Advanced Fabry Disease
|Annals of Internal Medicine|2007|565
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
|New England Journal of Medicine|2016|555
Acid sphingomyelinase deficient mice: a model of types A and B Niemann–Pick disease
|Nature Genetics|1995|477